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Abstract 
Background: Moldova experienced a nationwide mumps outbreak in 2007-2008. Single-dose 
monovalent mumps vaccination at 15-18 months was introduced in 1983, replaced by a two-
dose MMR schedule at age 1 and 6-7 years in 2002. We investigated the outbreak to quantify 
its extent, explore the role of primary and secondary vaccine failure, and provide control 
recommendations. 
Methods: We analyzed national mumps surveillance and vaccination coverage data to 
estimate vaccine effectiveness (VE) using the screening method. A retrospective cohort study 
in five educational institutions was conducted to determine age-specific attack rates (ARs) 
and VE. We compared vaccine strain-specific ARs. Isolation and genotyping of mumps virus 
strains were performed. 
Results: Of 31,142 cases reported during October 2007-July 2008, 80% were 15-24 years old. 
Of cases with information (66%), 92% were vaccinated once, 4% twice. One-dose mumps VE 
estimates based on surveillance data over 1997-2001 declined from 91% (95%CI 88-92%) in 
2 year-olds to 72% (70-74%) in 15-19 year-olds. In the cohort study (n=1,589), VE was -40% 
(-120 to 20%) for one dose. For two doses it was 62% (-43 to 90%) in 13-15 year-olds. ARs 
were higher in individuals vaccinated with Urabe strains (43%) than with Leningrad-Zagreb 
strains (14%, P<0.001). Mumps virus genotype G5 was identified. 
Conclusions: Low effectiveness of single-dose mumps vaccination was the main cause of the 
outbreak. Waning immunity may have contributed to this. The risk of mumps in two-dose 
vaccinees was low. Other countries in which large population groups have received <2 doses 
of mumps vaccine may face similar outbreaks. 
 




Since the 1960s, the introduction of mumps vaccination led to a dramatic decrease in mumps 
incidence (1;2). However, outbreaks of mumps in highly vaccinated populations have since 
been reported, raising questions about mumps vaccine effectiveness (VE) (2;3). Low VE may 
be due to primary vaccine failure (PVF, failure to mount an immune response), secondary 
vaccine failure (SVF, waning of vaccine-induced immunity) and reduced cross-protection 
against wild-type mumps virus (MuV) infection provided by the vaccine strain (4). 
All mumps vaccine strains, except Rubini, yielded efficacy estimates over 95% in the original 
accreditation randomized controlled clinical trials. However, lower effectiveness estimates 
were observed in outbreak studies, for example 77% for the Jeryl-Lynn and the Urabe strain 
(5). 
The Republic of Moldova (Moldova) introduced single-dose monovalent mumps vaccination in 
1983 for 15-18 month-old children. Vaccine strains used were Leningrad-3 (1983-1990), 
Leningrad-Zagreb and Urabe-Am9 (both after 1990). Vaccine shortages led to an interruption 
of the program in 1995-1996. Successful catch-up vaccination for affected birth cohorts was 
carried out in subsequent years. In 2002, a two-dose combined measles-mumps-rubella 
vaccination (MMR) schedule for 12 month-olds and 6-7 year-olds was introduced using Jeryl-
Lynn, Urabe-Am9, and Leningrad-Zagreb strains. Reported mumps vaccination coverage (VC) 
among birth cohorts from 1978 onwards exceeded 95%. A large mumps outbreak occurred in 
1996-1998 with 28,845 cases reported predominantly in individuals of early school-age (7-14 
years). From 1999 through 2004, the annual incidence of reported cases was <100, and as of 
2005 even <10 cases per 100,000 (6). 
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In October 2007, the monthly number of reported mumps cases increased to 105 compared to a 
monthly average of 24 from January-September. By the end of January 2008, a total of 6,613 
cases had been reported. Surveillance data indicated that a high proportion of cases had been 
vaccinated against mumps suggesting vaccine failure caused the outbreak. The aim of our 
investigation was to describe extent and characteristics of the outbreak, to explore the role of 
PVF and SVF, and to identify the genotype of the circulating mumps virus in order to 
contribute information regarding cross-protection afforded by the vaccine. 
 
Materials and Methods 
Outbreak description 
In Moldova, mumps is notifiable to the regional public health authorities when suspected on 
clinical grounds by health-care staff. Aggregated notification data are reported to the national 
level monthly and annually categorized into eight age-groups (<1, 1, 2, 3-6, 7-14, 15-19, 20-29, 
and >29 years). From week 51, 2007, cases were reported weekly in response to the outbreak. 
Assessment of vaccine effectiveness and the role of SVF 
We estimated the VE by the screening method (7) (see on-line appendix) and by carrying out a 
cross-sectional study at five educational institutions with high attack rates (AR; ≥10%), a wide 
age-range of pupils (6-24 years), available vaccination data, and available medical staff to assist 
with data collection. We used a self-administered questionnaire to collect information on socio-
demographic status, risk factors for exposure to mumps, disease history, symptoms, and 
hospital stay due to mumps. Study participants aged <15 years were asked to complete the 
questionnaire with their parents. We assumed implicit informed consent when the questionnaire 
was completed. Information on vaccination status, lot number and disease history for measles, 
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mumps, and rubella were obtained from the medical record of the sanitary service of the 
educational institution. The delivery register of the national vaccine store available from 1997 
onwards was used to link vaccine strains to lot numbers. We considered April-September as 
warm and October-March as cold season. We assumed that PVF due to cold chain failure is 
more likely to occur during the warm season. 
Mumps was defined as self-reported unilateral or bilateral tender, self-limited swelling of the 
parotid or other salivary gland lasting ≥2 days or as a mumps diagnosis in the medical record, 
with a date of onset after September 2007. We excluded individuals without vaccination 
records and those with a self-reported history of mumps before 2007. 
We compared ARs by age, educational institution, vaccine strain and season of vaccination 
using the Chi-square test. We estimated VE for one and two doses of mumps vaccine compared 
to zero doses, stratified by age-group, as 1-relative risk. Where group size permitted this, we 
calculated VE estimates adjusted for other risk factors according to the formula VE=1-odds 
ratio, whereby the odds ratio was estimated using multivariable logistic regression as outlined 
in the on-line appendix. Confidence intervals (CI) were calculated using the exact method. 
Stata version 10 was used for all analyses (8). 
Laboratory investigations 
Real-time MuV specific polymerase chain reaction (RT-PCR; (9)) was performed on oral fluid 
samples from 18 hospitalized patients. RT-PCR positive samples were confirmed by nested 







Between October 2007 and July 2008, 31,142 mumps cases were reported in all regions of 
Moldova. The outbreak peaked at the end of March 2008 (week 14) with 2,351 new cases. The 
monthly incidence increased from an average <1/100,000 in January-September 2007 to 
202/100,000 in March 2008 (Figure A1). 
Cases occurred in all age-groups. Forty percent were in 15-17 year-olds, 80% in 15-24 year-
olds; 58% were male. Thirty-six percent of cases were hospitalized, mainly for isolation 
purposes. No deaths due to mumps were reported. Vaccination status was available for 10,257 
(66%) of 15,540 cases notified between week 51/2007 and the start of supplementary 
immunization activities (SIA) in week 10/2008. Of these, 92% were vaccinated once against 
mumps, 4% twice. 
RT-PCR confirmed mumps in all tested samples. Eight samples were sequenced (Genbank 
number GQ370467) and all were an identical G5 genotype, similar to G5 sequences found in 
other parts of Europe. 
Cross-sectional study 
Three schools in rural areas, one college and one university (both in urban areas) participated to 
our cross-sectional study. Data were collected between 28 February and 5 March 2008. We 
received 1,820 completed (93% of distributed) questionnaires. We excluded 231 (13%) 
individuals from the analyses. The age-range of the remaining study population (n=1,589) was 
6-25 years (median 15), 54% were male. Ten percent were unvaccinated, 52% had received one 
dose and 35% two doses of mumps vaccine. 
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Of all participants, 294 met the case definition (AR 19%). The highest AR (42%) was in 16 
year-olds (Figure 1). ARs varied from 9% (university) to 27% (school 2) between study 
locations (P<0.001). Of the 294 cases, 11% were unvaccinated, 80% had received one dose and 
9% two doses of mumps vaccine. ARs did not differ between males (19%) and females (18%, 
P=0.81). 
Of 238 cases with available medical records (81%), parotid swelling was reported in 89%, 
pancreatitis in 27%, and hearing impairment in 7%. Orchitis was reported in 12% of male cases 
(63% of these bilateral). 
ARs in individuals vaccinated with one dose of monovalent mumps vaccine (n=819, 52%) were 
lower when the vaccine had been administered in the warm compared to the cold season (25% 
vs. 33%, P=0.02). In two-dose vaccinees (one dose of monovalent mumps followed by one 
dose of MMR vaccine, n=560) the ARs did not differ significantly by season of vaccination 
(P=0.28). 
We had information on used vaccine strain for 278/819 participants (34%) vaccinated with one 
dose of monovalent mumps vaccine between 1997 and 2002. The AR was 43% (30/70, 95%CI 
32-55%) in individuals vaccinated with the Urabe strain (between 1998 and 2001) and 14% 
(29/208, 95%CI 9-19%) in individuals vaccinated with the Leningrad-Zagreb strain (all in 
1997). 
The adjusted VE for one dose of monovalent mumps vaccine was -40% (95%CI -120 to 20%). 
There was a trend of a decrease in adjusted VE by age-group. We could not calculate an 
adjusted VE for two doses of mumps vaccine (one dose of monovalent followed by one dose of 
MMR) due to low numbers of individuals. The crude VE for two doses was 62% (-43 to 90%) 
in 13-15 year-olds (Table 1). 
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Results from the risk factor analysis and the historical VE which were estimated using the 
screening method are presented in the on-line appendix. 
 
Discussion 
Between October 2007 and July 2008 Moldova faced a large nationwide mumps outbreak. 
Most cases were in teenagers and young adults (15-24 years) vaccinated with one dose of 
mumps vaccine. The adjusted VE for one dose of monovalent mumps vaccine in a study cohort 
was very low (-40%). There was a decline in VE with increasing age. We found some evidence 
for a higher AR in individuals vaccinated once with the Urabe strain compared with the 
Leningrad-Zagreb strain. 
Our cohort study was designed with the primary aim to identify reasons for vaccine failure, as 
the vast majority of cases occurred in vaccinated individuals. It lacked power to estimate the 
VE with adequate precision. Our estimated VE for one dose of monovalent mumps vaccine was 
below zero, which is biologically not plausible. Circulation of MuV in Moldova in the past, 
notably during the 1997/98 outbreak, would have infected unvaccinated individuals at a higher 
rate leading to an underestimation of the AR in unvaccinated and thus underestimating the VE. 
Although we excluded individuals with a history of mumps, residual confounding is likely to be 
present as mumps is often asymptomatic. 
Explanations for the low VE estimates include SVF and PVF and reduced cross-protection 
afforded by vaccine strains against the outbreak strain. 
We observed a decrease in mumps VE with age for one dose of mumps vaccine, both in our 
cross-sectional study and by using the screening method. This would be consistent with SVF. 
However, residual confounding due to past infection is probably stronger in older age-groups 
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and limits the conclusions that can be drawn from the observed decline in VE by age-group. A 
planned serological study of pre-outbreak samples will provide information on age-specific pre-
existent immunity and aid interpretation of our VE estimates. 
Waning of mumps vaccine-induced immunity has been suggested in other outbreak 
investigations (11;12). Serological surveys in high-coverage settings with low wild MuV 
exposure suggest a decrease of anti-MuV antibodies over time. However, to date this has not 
been shown to be linked to a decrease in protection (13-16). There is also evidence for long 
persistence of cellular immunity (17). This is supported by other studies where no evidence for 
waning immunity was found (18;19). 
Our analyses regarding PVF were limited to comparing season of vaccine administration and 
did not include other potential reasons for PVF as only anecdotal information on this was 
available. We cannot explain the higher AR in individuals vaccinated in the cold season, but 
our results argue against a cold chain failure. 
Reduced cross protection afforded by vaccine strains against the G5 strain might have 
contributed to the extent of this outbreak. Good cross protection between genotypes has been 
observed in several outbreaks (20;21) and there is serological and phylogenetic evidence of 
monotypic immune response to different MuV strains (22). However, lower levels of 
neutralizing antibody titers against antigenically different MuV strains have been demonstrated 
(23), and the level of cross protection may depend on absolute antibody levels. Other studies 
also provided some evidence for mumps vaccine-induced immunity being less effective against 
heterologous wild virus strains (3;23-25). A population-based serosurvey which will allow 
assessing the level of protection provided by vaccine-induced antibodies against different wild-
type MuV strains is currently being carried out. 
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The proportion of orchitis in males is comparable to what has been reported elsewhere (5), 
however, the proportion of cases with pancreatitis is probably an overestimation as the 
diagnosis was based on elevated serum amylase irrespective of clinical symptoms. The 
hospitalization rates were much higher than reported for other mumps outbreaks (3), however, 
the majority was hospitalized for isolation purposes. Considering the peak in infectivity prior to 
symptom onset in mumps (26) hospitalization is unlikely to contribute to mumps control. 
The mumps outbreak with >31,000 cases overwhelmed the Moldovan health system. Our 
findings, and those elsewhere (27), suggest that countries where large population groups have 
received less than two doses of mumps vaccination may experience outbreaks, and support 
WHO’s recommendation of introducing a second dose of mumps vaccine in the routine 
vaccination schedule (28). Countries should assess the need to offer a second dose of mumps 
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Figure 1: Number of cohort study participants and attack rate (AR) by age, Republic of 
Moldova, March 2008 (n=1,589). 
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Table 1: Attack rates (ARs) and (adjusted = a) vaccine effectiveness (VE) estimates by age-group for a single dose of monovalent mumps vaccine 
and the combination of 1 dose of monovalent mumps followed by 1 dose of MMR vaccine derived from the cohort study, Republic of Moldova, 
March 2008. 
  
0 doses  1 dose (monovalent mumps vaccine)  
2 doses (monovalent mumps 
followed by MMR vaccine) 
Age (years)  n AR 
(%) 
















6-9  (N=251)  1 0  7 0 - - - -  243 0.4 - - 
10-12 (N=293)  0 -  5 0 - - - -  288 6.6 - - 
13-15 (N=375)  13 30.8  336 24.4 21 -0.8 to 66 30 -140 to 80  26 11.5 62 -43 to 90 
16-19 (N=518)  108 23.2  410 34.2 -48 -113 to -2 -40 -140 to 20  0 - - - 
20-25 (N=105)  41 4.9  62 16.1 -230 -1332 to 24 -200 -1,470 to 40  2 - - - 
Total (N=1,542)  163 19.0  820 28.3 -49 -108 to -6 -40 -120 to 20  559 4.1 - - 
Note.-CI=confidence interval. 
*Calculations of aVE estimates based on 13-25 year-old individuals with information on all variables included in the multivariable model (n=910, see Table A1). 
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Appendix: supplementary on-line material. 
 
Risk factors for mumps in 13-25 year-old individuals 
To asses associations between case status and exposure risk factors, we used a self-
administered questionnaire with information on socio-demographic status, risk factors for 
exposure to mumps, disease history, symptoms, and hospital stay due to mumps. Study 
participants aged <15 years were asked to complete the questionnaire with their parents. 
Information on vaccination status and disease history for measles, mumps, and rubella were 
taken from the medical records kept at the sanitary service of the educational institutions. The 
risk factor analysis was restricted to the age-groups with unvaccinated individuals, i.e. 13-25 
years. In younger age-groups nearly all children had two doses of mumps vaccination. Only 
one individual between six and nine years of age and nobody between 10 and 12 years was 
unvaccinated. We explored potential risk factors in 13-25 year-old individuals unvaccinated 
or vaccinated with one dose of monovalent mumps vaccine and with information on all 
variables using univariable and multivariable logistic regression. 
We included 910 individuals (57% of total study population) in the analyses. Reported contact 
with a mumps case and being a dormitory resident were associated with having mumps after 
adjusting for other variables. Participants from the college and the university faculty had a 
lower risk of getting mumps (Table A1). 
 
Estimates of historical vaccine effectiveness in Moldova (1997-2001) 
To estimate historic vaccine effectiveness (VE) we applied the ”screening method” 
(Reference A1),  using national surveillance data whereby VE=(PPV-PCV)/(PPV*[1-PCV]), 
with PPV=proportion of the population vaccinated, PCV=proportion of cases vaccinated. We 
calculated exact 95% CIs around the PCV and entered them into the formula to obtain 95% 
confidence intervals (CIs) around VE estimates,. To obtain PPV estimates, the regional health 
authorities annually review the vaccination status of registered children from the ten youngest 
 A2 
birth cohorts, e.g. in 2003 PPV estimates were obtained for birth cohorts 1993-2002. We used 
the most recent PPV estimate for each birth cohort, e.g. the PPV estimate from 2002 for the 
birth cohort 1992. We used mumps surveillance data for the period 1997-2001 to estimate the 
VE by age-group. Data from before 1997 (incomplete data) and after 2001 (insufficient 
number of unvaccinated cases) were excluded. 
The average PPV between 1997 and 2001 was 89%, 89%, 95% and 82% in 2, 3-6, 7-14 and 
15-19 year-olds, respectively. In 1997-2001 the estimated VE for a single dose of mumps 
vaccine decreased from 91% in 2 year-olds to 72% in 15-19 year-olds (Table A2). For older 
age-groups PPV estimates were not available and VE could therefore not be estimated. 
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Figure A1: Notified mumps cases by month, Republic of Moldova, July 2007 – July 2008 
(n=31,203). 
 
Table A1: Results of the risk factor analysis using univariable and multivariable logistic 
regression, cohort study, Republic of Moldova, March 2008. The models include 13-25 year-
old individuals unvaccinated or vaccinated with one single dose of monovalent mumps 
vaccine and with information on all variables (n=910). 
  Univariable 
Analysis 
 Multivariable analysis 
Baseline odds=0.14 
Pseudo R2=0.07 
Risk factor  OR 95%CI  aOR 95%CI 
Educational setting       
School 1  Ref.   Ref.  
School 2  1.7 1.1-2.6  1.1 0.7-1.9 
School 3  1.4 0.9-2.1  1.0 0.7-1.6 
College  1.0 0.6-1.4  0.3 0.1-0.7 
University faculty  0.3 0.1-0.7  0.1 <0.1-0.5 
Mumps vaccination       
Unvaccinated  Ref.   Ref.  
1 dose monovalent  1.7 1.1-2.7  1.4* 0.8-2.2* 
     stratified by age-group 
13-15 years     0.7 0.2-2.4 
16-19 years     1.4 0.8-2.4 
20-25 years     3.0 0.6-15.7 
Age-group (years)       
13-15  Ref.   Ref.  
16-19  1.5 1.1-2.1  0.9 0.2-3.5 
20-25  0.4 0.2-0.8  0.4 0.1-2.7 
Female sex  1.1 0.8-1.5  1.1 0.8-1.5 
Risk factors for exposure       







Weekly use of public transport  1.1 0.8-1.5  1.3 0.9-1.8 
Living in a dormitory  0.9 0.6-1.2  2.2 1.1-4.4 
Living with ≥3 co-residents  0.8 0.6-1.1  0.8 0.5-1.1 
Note: (a)OR = (adjusted) odds ratio; CI = confidence interval; Ref. = reference group. 
*Overall aOR for one dose of monovalent mumps vaccine was derived from separate model that included 
the same co-variables. 
 
Table A2: Proportion of population vaccinated (PPV), proportion of cases vaccinated (PCV), 
vaccine effectiveness (VE) estimates and 95% confidence intervals (CI) by age-group for a 
single dose of monovalent mumps vaccine, derived from routine surveillance data using the 


















2 89 149 344 43 91 88-92 
3-6 89 1720 4779 35 93 93-94 
7-14 95 11690 15561 75 84 84-85 
15-19 82 2143 3820 56 72 70-74 
 
